Key result
Orally active factor Xa inhibitors demonstrate promising antithrombotic efficacy and safety profiles in preclinical models, suggesting their potential as innovative new anticoagulants.
Why the study?
Does the oral FXa inhibitor TAK-239 improve neurological deficits and reduce infarct size in a primate model of thromboembolic stroke?
Does the oral FXa inhibitor TAK-239 improve neurological deficits and reduce infarct size in a primate model of thromboembolic stroke?
Preclinical data demonstrate that the oral FXa inhibitor TAK-239 improves neurological deficits and survival in a primate model of thromboembolic stroke, supporting the potential of FXa inhibitors as novel anticoagulants.
Answers are grounded in this paper and cite their sources.
May advance oral FXa inhibitors to clinical trials; leaves open translation of primate stroke benefits to humans.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Konishi et al. (2010) conducted a review in Thrombosis. Orally active factor Xa (FXa) inhibitors vs. Warfarin or other standard anticoagulants was evaluated. Orally active factor Xa inhibitors demonstrate promising antithrombotic efficacy and safety profiles in preclinical models, suggesting their potential as innovative new anticoagulants.
Synapse has enriched 10 related papers. Consider them for comparative context: